We evaluated efficacy of natalizumab in relapsing-remitting multiple sclerosis patients in a clinical practice setting. We report data on the first consecutive 343 patients receiving natalizumab in 12 multiple sclerosis (MS) Italian centers enrolled between April 2007 and November 2010. The main efficacy endpoints were the proportion of patients free from relapses, disease progression, combined clinical activity, defined as presence of relapse or disease progression, from MRI activity, and from any disease activity defined as the absence of any single or combined activity. At the end of follow-up, the cumulative proportion of patients free from relapses was 68%; the proportion of patients free from Expanded Disability Status Scale (EDSS) pr...
Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relap...
Natalizumab (Tysabri®) is highly efficacious in controlling disease activity in relapsing multiple s...
Francesco Patti, Angelo PappalardoMultiple Sclerosis Center, University of Catania, Catania, Italy; ...
We evaluated efficacy of natalizumab in relapsing-remitting multiple sclerosis patients in a clinica...
We reported a post-marketing experience of 190 patients affected by relapsing multiple sclerosis on ...
Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab tre...
We report our experience in long-term treatment of relapsing remitting multiple sclerosis patients w...
In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were ...
Background: Both natalizumab and fingolimod are highly effective in the treatment of relapsing-remit...
Natalizumab is one option for multiple sclerosis patients responding poorly to classical immunomodul...
IMPORTANCE The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients...
Natalizumab (Tysabri(®)) is highly efficacious in controlling disease activity in relapsing multiple...
Clinical trials have shown that natalizumab is highly effective for treating relapsing forms of mult...
Three years after the introduction of natalizumab (NA) therapy for the second line treatment of rela...
Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relap...
Natalizumab (Tysabri®) is highly efficacious in controlling disease activity in relapsing multiple s...
Francesco Patti, Angelo PappalardoMultiple Sclerosis Center, University of Catania, Catania, Italy; ...
We evaluated efficacy of natalizumab in relapsing-remitting multiple sclerosis patients in a clinica...
We reported a post-marketing experience of 190 patients affected by relapsing multiple sclerosis on ...
Objective Analyze the demographics, clinical characteristics, efficacy and safety of natalizumab tre...
We report our experience in long-term treatment of relapsing remitting multiple sclerosis patients w...
In patients with either relapsing-remitting or secondary-progressive multiple sclerosis, there were ...
Background: Both natalizumab and fingolimod are highly effective in the treatment of relapsing-remit...
Natalizumab is one option for multiple sclerosis patients responding poorly to classical immunomodul...
IMPORTANCE The evaluation of therapeutic choices is needed after 24 doses of natalizumab in patients...
Natalizumab (Tysabri(®)) is highly efficacious in controlling disease activity in relapsing multiple...
Clinical trials have shown that natalizumab is highly effective for treating relapsing forms of mult...
Three years after the introduction of natalizumab (NA) therapy for the second line treatment of rela...
Three years after the introduction of natalizumab(NA) therapy for the second line treatment of relap...
Natalizumab (Tysabri®) is highly efficacious in controlling disease activity in relapsing multiple s...
Francesco Patti, Angelo PappalardoMultiple Sclerosis Center, University of Catania, Catania, Italy; ...